Despite clear guideline recommendations and widespread statin use, the majority of secondary prevention patients, particularly those at very high risk, fail to achieve recommended LDL-C thresholds. For these patients, the addition of nonstatin strategies is warranted to decrease residual risk. Clinicians frequently delay treatment escalation despite persistent LDL-C elevation, reflecting uncertainty around the timing, sequencing, and tolerability of additional therapies. Emerging phase 3 data are providing evidence for new approaches in this setting, including the CETP inhibitor obicetrapib, which has shown stronger efficacy and safer toxicity findings compared to older CETP inhibitors. Moreover, other data indicate that obicetrapib is active in renal and metabolic diseases, as well as in Alzheimer’s disease. In this activity, expert faculty explore best practices in ASCVD management and the potential role of CETP inhibitors in this setting.
Advancing Lipid Care: CETP Inhibition and Overcoming Inertia in Modern ASCVD Management
Overview
Disclosure of Relevant Financial Relationships
In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative requires all faculty and planners to disclose financial relationships with ineligible companies. All relevant financial relationships have been reviewed and mitigated to ensure that the content is free from commercial bias.
The following faculty and planners have disclosed relevant financial relationships with ineligible companies in the past 24 months.
Faculty:
Christie Ballantyne, MD
Chief, Sections of Cardiology and Cardiovascular Research
Department of Medicine
Baylor College of Medicine
Houston, TXAdvisor/Consultant: 89Bio, Abbott Diagnostics, Amgen, Arrowhead, AstraZeneca, Denka Seiken, Esperion, Genentech, HeartFlow, Ionis, Eli Lilly, Merck, NewAmsterdam, Novartis, Novo Nordisk, Roche Diagnostic
Contracted Researcher: Abbott Diagnostic, Akcea, Amgen, Arrowhead, Ionis, Eli Lilly, Merck, New Amsterdam, Novartis, Novo Nordisk, Roche DiagnosticErin Michos, MD, MHS
Professor of Medicine
John Hopkins University Schoolof Medicine
Baltimore, MDConsulting Fees: Amgen, Arrowhead Pharmaceuticals, AstraZeneca, Bayer, Boehringer Ingelheim, Edwards Lifesciences, Eli Lilly and Company, Hello Heart, Ionis Pharmaceuticals, Merck, Mineralys Therapeutics, NewAmsterdam Pharma, Novartis, Novo Nordisk
Philip Scheltens, MD, PhD
Professor Emeritus
Alzheimer Center
Amsterdam University Medical Center
Amsterdam, the NetherlandsPhilip Scheltens, MD, PhD has no relevant relationships to disclose.
Reviewers/Planners/Authors:
- Tim Person has no relevant relationships to disclose.
- Wilma M. Guerra has no relevant relationships to disclose.
- Brian P. McDonough, MD, FAAFP has no relevant relationships to disclose.
Learning Objectives
Upon completion of this activity, learners should be better able to:
- Reassess the role of CETP inhibition and broader lipid modification in ASCVD risk reduction using contemporary mechanistic and clinical evidence
- Apply evidence-based and guideline-aligned strategies to identify residual risk and initiate timely lipid-lowering therapy intensification in patients with ASCVD
- Evaluate the efficacy and safety profile of emerging lipid-lowering therapies, including their broader metabolic and systemic effects, to inform clinical decision-making
- Integrate lipoprotein(a)/genetic assessment into cardiovascular risk stratification and apply its findings to guide treatment decision-making
Target Audience
This activity has been designed to meet the educational needs of cardiologists and primary care physicians as well as all other physicians, physician assistants, nurse practitioners, nurses, pharmacists, and healthcare professionals involved in managing patients with atherosclerotic cardiovascular disease (ASCVD).
Accreditation and Credit Designation Statements
In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Global Learning Collaborative (GLC) designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 1.00 nursing contact hour(s). Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) has been authorized by the American Academy of Physician Associates (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credit(s). PAs should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for a maximum of 1.00 contact hour(s) (0.10 CEUs) of pharmacy continuing education credit.The Universal Activity Number (UAN) for this program is JA0006235-0000-26-141-H01-P. This learning activity is knowledge-based. Upon successful completion of the activity, continuing education credit will be electronically submitted to the National Association of Boards of Pharmacy (NABP). Pharmacists with questions may contact NABP Customer Service at custserv@nabp.net.
Provider(s)/Educational Partner(s)
Our ultimate goal is to improve the care being delivered to patients, and our high-quality, evidence-based CME initiatives reflect our dedication to the creation and execution of excellence and are the product of shared research, knowledge, and clinical practice skills across the healthcare continuum.
Commercial Support
This activity is supported by an independent educational grant from New Amsterdam Pharma B.V.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Medtelligence. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information.
Reproduction Prohibited
Reproduction of this material is not permitted without written permission from the copyright owner.System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
- Apple Safari for Mac OS and iOS
- Mozilla Firefox for Windows, Mac OS, iOS, and Android
- Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Publication Dates
Release Date:
Expiration Date:
